Bolt Biotherapeutics, Inc. (BOLT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
BOLT currently has 1.92M outstanding shares. with moderate dilution risk from 604K authorized shares representing 31.4% potential dilution. The company has minimally diluted shareholders by 3.62% over the past 2 years. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 12, 2026 |
10-Q filing | 1.9M shares outstanding |
1.9M | 600K |
| Mar 12, 2026 |
10-K filing | 1.9M shares outstanding |
1.9M | 600K |
| Nov 12, 2025 |
10-Q filing | 1.9M shares outstanding |
1.9M | 600K |
| Aug 14, 2025 |
10-Q filing | 1.9M shares outstanding |
1.9M | 600K |
| Jun 06, 2025 |
Stock Split
8-K filing: Stock split 1-for-20 | Outstanding: 38,339,697 → 1,916,984 |
1.9M | 30K |
| May 12, 2025 |
10-Q filing | 38.3M shares outstanding |
38M | 12M |
| Mar 24, 2025 |
10-K filing | 38.2M shares outstanding |
38M | 12M |
| Nov 12, 2024 |
10-Q filing | 38.3M shares outstanding |
38M | 12M |
| Aug 13, 2024 |
10-Q filing | 38.1M shares outstanding |
38M | 12M |
| May 14, 2024 |
10-Q filing | 38.1M shares outstanding |
38M | 12M |
| Mar 21, 2024 |
10-K filing | 37.8M shares outstanding |
38M | 12M |
| Nov 09, 2023 |
10-Q filing | 37.9M shares outstanding |
38M | 12M |
| Aug 07, 2023 |
10-Q filing | 37.8M shares outstanding |
38M | 12M |
| May 11, 2023 |
10-Q filing | 37.7M shares outstanding |
38M | 12M |
| Mar 29, 2023 |
10-K filing | 37.4M shares outstanding |
37M | 12M |
| Nov 10, 2022 |
10-Q filing | 37.5M shares outstanding |
37M | 12M |
| Aug 10, 2022 |
10-Q filing | 37.5M shares outstanding |
38M | 12M |
| May 12, 2022 |
10-Q filing | 37.4M shares outstanding |
37M | 12M |
| Mar 30, 2022 |
S-3 filing: The company may offer and sell up to an aggregate amount of $250,000,000 of any combination of common stock, preferred stock, debt securities and warrants. |
37M | 12M |
| Mar 30, 2022 |
10-K filing | 37.5M shares outstanding |
37M | 12M |
| Nov 09, 2021 |
10-Q filing | 37.2M shares outstanding |
37M | 12M |
| Aug 12, 2021 |
10-Q filing | 36.6M shares outstanding |
37M | 12M |
| May 13, 2021 |
10-Q filing | 36.3M shares outstanding |
36M | 12M |
| Feb 03, 2021 |
S-1/A filing: This S-1/A filing details an offering of 10,500,000 shares of common stock, with an option for underwriters to purchase an additional 1,575,000 shares. The company intends to use the net proceeds from this offering to conduct our clinical trials, to fund continued research and development of BDC-1001, to fund other research and development activities, and for working capital and other general corporate purposes. |
23M | 12M |
| Feb 01, 2021 |
S-1/A filing: This S-1/A filing details a proposed public offering of Bolt Biotherapeutics, Inc.'s common stock, with 8,825,000 shares offered and an option for underwriters to purchase an additional 1,323,750 shares. |
23M | 10M |
| Jan 15, 2021 |
S-1 filing: This is an S-1 filing for an initial public offering of common stock. |
160M | 0 |